Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 24, 2020

Primary Completion Date

January 31, 2023

Study Completion Date

May 30, 2023

Conditions
Coronary Artery DiseaseIschemiaAngina RefractoryCardiovascular DiseasesHeart Diseases
Interventions
BIOLOGICAL

AdVEGFXC1

AdVEGFXC1 at one of 4 doses

Trial Locations (16)

18103

Lehigh Valley Health Network, Allentown

20010

MedStar Washington Hospital Center, Washington D.C.

27710

Duke University, Durham

30322

Emory University, Atlanta

32117

Cardiology Research Associates, Daytona Beach

32610

University of Florida, Gainesville

33612

James A. Haley VA Medical Center, Tampa

43210

The Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

45219

The Christ Hospital / The Lindner Research Center, Cincinnati

45267

University of Cincinnati, Cincinnati

55407

Minneapolis Heart Institute Foundation, Minneapolis

77030

Houston Methodist, Houston

Texas Heart Institute, Houston

94305

Stanford University, Stanford

98195

University of Washington, Seattle

All Listed Sponsors
lead

XyloCor Therapeutics, Inc.

INDUSTRY

NCT04125732 - Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial) | Biotech Hunter | Biotech Hunter